Recombinant Human Thrombopoietin in Combination With Rituximab in Immune Thrombocytopenia (ITP)

NCT01506414 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

91

Enrollment

OTHER

Sponsor class

Conditions

Purpura
Idiopathic Thrombocytopenic Purpura

Interventions

DRUG: rhTPO in combination with Rituximab

Sponsor

Ming Hou

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]